SEC Form 20-F filed by LakeShore Biopharma Co. Ltd
$LSB
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter (the "Proposal Letter"), dated August 18, 2025, from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (collectively, "Oceanpine Capital") to acquire all of the outstanding ordinary shares, par value US$0.0002 per share, of the Company (the "Ordinary Shares") th
Total revenue reached RMB615.0 million, representing 7.2% year-over-year growthGross profit rose to RMB507.2 million, up 11.3% year-over-yearGross margin improved to 82.5% from 79.5% in Fiscal Year 2024Total operating expenses decreased 34.2% year-over-year to RMB593.5 millionEBITDA[1] and Adjusted EBITDA[2] were RMB(48.5 million) and RMB0.6 million, respectively, compared to RMB(368.7 million) and RMB(236.4 million) in Fiscal Year 2024Net loss narrowed to RMB100.0 million, with an adjusted net loss[3] of RMB40.0 million, compared to RMB433.5 million and RMB266.3 million, respectively, in Fiscal Year 2024BEIJING, July 31, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeS
BEIJING, July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into a share and warrant purchase agreement (the "Purchase Agreement") with an institutional investor for the issuance and sale of 16,987,542 ordinary shares of the Company, par value US$0.0002 per share, at US$0.883 per share, and 16,987,542 warrants, each entitling the institutional investor to purchase one ordinary share at an exercise price of US$1.079 at any time and
6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)
6-K - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)
20-F - LakeShore Biopharma Co., Ltd. (0001946399) (Filer)
Total revenue reached RMB615.0 million, representing 7.2% year-over-year growthGross profit rose to RMB507.2 million, up 11.3% year-over-yearGross margin improved to 82.5% from 79.5% in Fiscal Year 2024Total operating expenses decreased 34.2% year-over-year to RMB593.5 millionEBITDA[1] and Adjusted EBITDA[2] were RMB(48.5 million) and RMB0.6 million, respectively, compared to RMB(368.7 million) and RMB(236.4 million) in Fiscal Year 2024Net loss narrowed to RMB100.0 million, with an adjusted net loss[3] of RMB40.0 million, compared to RMB433.5 million and RMB266.3 million, respectively, in Fiscal Year 2024BEIJING, July 31, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeS
Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoYAchieved gross profit of RMB 307.3 million, a growth of 39.1% YoYGross margin increased to 82.6% from 80.9% in the same period of FY2024Total operating expenses decreased to RMB 276.4 million, down 31.6% YoYRecorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted net loss[1] (Non-GAAP) of RMB 174.5 million in the same period of FY2024BEIJING, Dec. 19, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deli
GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on September 27, 2024 (Beijing Time) virtually via a Zoom video conference call. The EGM was called as part of the Company's efforts to regain compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1).
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the board of directors of the Company (the "Board") has appointed Mr. Xu Wang as the Chief Executive Officer of the Company. He succeeds Mr. Dave Chenn and Dr. Hui Shao, who step down from the Company's Interim Chief Executive Officer and Co-Chief Executive Officer position, respectively. Mr. Xu Wang has served as the Company's Chief Operation Office